Picard Medical, Inc. — Form 8-K Summary
Filing date: October 6, 2026. Reported event: September 30, 2026. This filing reports a financing transaction, not quarterly or annual operating results.
Business context and transaction
On September 30, 2026, Picard Medical issued three unsecured convertible notes to three accredited investors with an aggregate principal amount of $1.0 million. The notes mature September 30, 2027.
Financial terms and potential dilution
- Each note bears interest at 3.0% per year, calculated on a 360-day basis. The outstanding balance includes unpaid principal and accrued unpaid interest.
- Each holder may convert its note balance before repayment or maturity. The conversion price is the higher of $4.00 per share and the common stock closing price on the trading day before the conversion notice.
- At the $4.00 floor price, the $1.0 million principal could convert into up to 250,000 common shares, excluding shares for accrued interest. For each share issued on conversion, the company will also issue a pre-funded warrant to purchase one share; the warrants carry a $0.0001 exercise price and a two-year term, and become exercisable 60 days after issuance.
- Conversion and warrant exercise may dilute existing shareholders. Holder conversions are limited if they would cause a holder and its affiliates to own more than 4.99% of outstanding common stock.
- Until required stockholder approval is obtained, the company will not issue shares upon conversion or warrant exercise to the extent aggregate issuance under the notes and warrants would exceed 19.99% of shares outstanding on the issuance date.
- If the company completes an equity financing before maturity that raises at least $10.0 million in gross cash proceeds, it may elect to convert the outstanding note balances into shares. The price would be the higher of $4.00 per share and the financing price, subject to the notes’ terms and limitations.
Operating results, liquidity, and outlook
The filing provides no revenue, profit, cash-flow, margin, cash-balance, or other operating-performance figures, and does not state a clear amount of net cash proceeds from the note issuance. It includes no business guidance or operating outlook.
Risks, contingencies, and unusual terms
- Upon an event of default, including specified payment failures, covenant breaches, or bankruptcy or insolvency events, a holder may declare its note’s outstanding balance immediately due and payable.
- The notes and warrants are subject to NYSE American requirements. Securities issuances rely on applicable registration exemptions, subject to the conditions for those exemptions being met.
Key facts for investors to verify
- Review Exhibits 4.1 and 4.2 for the complete note and warrant terms, including definitions, limitations, and remedies.
- Check whether holders exercise conversion rights, whether warrants are issued or exercised, and the resulting dilution.
- Monitor any required stockholder approval and the 19.99% issuance limit.
- Verify whether a qualifying $10.0 million equity financing occurs and whether the company elects to convert the notes.